Can a smart drug starve liver tumors without harming healthy tissue?
Disease control
Stopped early
This trial tests a new biologic called CSR02-Fab-TF, given directly into the liver's blood supply, for people with intermediate or limited advanced liver cancer that has not responded to prior treatment. The drug is designed to block blood vessels that feed the tumor while sparin…
Early phase 1 • Sponsor: Koo Foundation Sun Yat-Sen Cancer Center • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC